论文部分内容阅读
目的探讨BACOP/BACODP交替联合化疗方案治疗非霍奇金淋巴瘤(NHL)的疗效与毒副反应。方法本组患者均应用BACOP/BACODP交替联合化疗方案治疗。化疗后残留病灶行局部放疗。结果完全缓解率为69.6％,总有效率为91.2％,1、3、5年生存率分别为70.5％、65.6％和62.7％。初治患者完全缓解率为73.8％,1、3、5年生存率分别为72.6％、68.6％和66.90%;复治患者完全缓解率为45.6％,1、3、5年生存率分别为57.5％、47.9％和38.3％。毒副反应均可耐受。结论BACOP/BACODP交替联合化疗方案有助于减少耐药细胞株产生,从而提高完全缓解率和远期生存率,且毒副反应可以耐受。
Objective To investigate the curative effect and toxicity of BACOP / BACODP combined with chemotherapy on non-Hodgkin’s lymphoma (NHL). Methods The patients were treated with BACOP / BACODP alternating chemotherapy. Residual lesions after chemotherapy with local radiotherapy. Results The complete remission rate was 69.6%, the total effective rate was 91.2%, and the 1,3 and 5-year survival rates were 70.5%, 65.6% and 62.7%, respectively. The complete remission rate was 73.8% in initial treatment and 72.6%, 68.6% and 66.90% respectively in 1,3,5-year-old patients. The complete remission rate was 45.6% in re-treatment and 1-year, 3-year and 5-year survival rates were 57.5 %, 47.9% and 38.3%. Toxicity can be tolerated. Conclusion The combination of BACOP / BACODP and chemotherapy can help reduce the generation of drug-resistant cell lines, thus improving the complete remission rate and long-term survival rate, and the toxicity can be tolerated.